BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34997317)

  • 21. MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib.
    Jonas K; Prinz F; Ferracin M; Krajina K; Pasculli B; Deutsch A; Madl T; Rinner B; Slaby O; Klec C; Pichler M
    Breast Cancer Res; 2023 Oct; 25(1):119. PubMed ID: 37803350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
    Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
    Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling.
    Vishnubalaji R; Alajez NM
    Sci Rep; 2021 Jul; 11(1):15410. PubMed ID: 34326372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression.
    Fan H; Yuan J; Li X; Ma Y; Wang X; Xu B; Li X
    Biomed Pharmacother; 2020 May; 125():109987. PubMed ID: 32058222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of the Novel Tumor Suppressor Role of FOCAD/miR-491-5p to Inhibit Cancer Stemness, Drug Resistance and Metastasis via Regulating RABIF/MMP Signaling in Triple Negative Breast Cancer.
    Huang WC; Chi HC; Tung SL; Chen PM; Shih YC; Huang YC; Chu PY
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
    Zheng S; Li M; Miao K; Xu H
    J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epithelial-mesenchymal transition induced PAI-1 is associated with prognosis of triple-negative breast cancer patients.
    Xu J; Zhang W; Tang L; Chen W; Guan X
    Gene; 2018 Sep; 670():7-14. PubMed ID: 29802992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2.
    Zhang G; Li H; Sun R; Li P; Yang Z; Liu Y; Wang Z; Yang Y; Yin C
    J Cell Mol Med; 2019 May; 23(5):3271-3279. PubMed ID: 30825262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling.
    Han C; Li X; Fan Q; Liu G; Yin J
    Aging (Albany NY); 2019 Jul; 11(14):4858-4875. PubMed ID: 31310241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The long noncoding RNA sONE represses triple-negative breast cancer aggressiveness through inducing the expression of miR-34a, miR-15a, miR-16, and let-7a.
    Youness RA; Hafez HM; Khallaf E; Assal RA; Abdel Motaal A; Gad MZ
    J Cell Physiol; 2019 Nov; 234(11):20286-20297. PubMed ID: 30968427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p.
    Peng Y; Huang X; Wang H
    BMC Mol Cell Biol; 2022 Jul; 23(1):34. PubMed ID: 35896973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long non-coding RNA SNHG8 enhances triple-negative breast cancer cell proliferation and migration by regulating the miR-335-5p/PYGO2 axis.
    Qian J; Lei X; Sun Y; Zheng L; Li J; Zhang S; Zhang L; Li W; Shi J; Jia W; Tang T
    Biol Direct; 2021 Aug; 16(1):13. PubMed ID: 34362407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LncRNA HEIH/miR-939-5p interplay modulates triple-negative breast cancer progression through NOS2-induced nitric oxide production.
    Nafea H; Youness RA; Abou-Aisha K; Gad MZ
    J Cell Physiol; 2021 Jul; 236(7):5362-5372. PubMed ID: 33368266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LncRNA DANCR contributes to tumor progression via targetting miR-216a-5p in breast cancer: lncRNA DANCR contributes to tumor progression.
    Tao W; Wang C; Zhu B; Zhang G; Pang D
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA.
    Hao Q; Wang P; Dutta P; Chung S; Li Q; Wang K; Li J; Cao W; Deng W; Geng Q; Schrode K; Shaheen M; Wu K; Zhu D; Chen QH; Chen G; Elshimali Y; Vadgama J; Wu Y
    Cell Death Dis; 2020 Dec; 11(12):1052. PubMed ID: 33311440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p.
    Xing L; Tang X; Wu K; Huang X; Yi Y; Huan J
    Aging (Albany NY); 2020 Dec; 13(1):424-436. PubMed ID: 33290256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
    Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
    BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
    Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
    Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway.
    Liu G; Wang P; Zhang H
    J Gene Med; 2019 Dec; 21(12):e3129. PubMed ID: 31693779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.